IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

27. November 08:30 Allianz: Ausverkaufskurse am Freitag – jetzt nachziehen?

27. November 08:45 Begehrt wie Tesla, brandheiß wie Plug Power, gefragt wie Nvidia: ...

27. November 08:45 Kolumne: Ein Frühjahrsaufschwung zeichnet sich ab

27. November 09:00 Top-Tipp Derivate: Auf der Überholspur

27. November 09:30 Play-Magnus-Chef im Exklusiv-Interview: So will Andreas Thome das ...

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021